{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023837","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.274765+00:00","generated_at":"2026-06-22T01:49:17.832945+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Graphite Bio doses first patient with nula-cel; Q3 net loss $24.7M; cash runway into Q4 2024","bullets":["Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023.","Q3 net loss $24.7M ($0.45 per share); R&D expenses $18.3M, G&A $7.9M.","Cash, equivalents and investments $305.1M as of Sep 30, 2022; runway into Q4 2024.","Entered strategic manufacturing partnership with WuXi Advanced Therapies for nula-cel.","Two abstracts accepted for ASH 2022; hired Darren Hart as SVP of development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023837","json":"https://secwatch.observer/filing/0000950170-22-023837.json","markdown":"https://secwatch.observer/filing/0000950170-22-023837.md","text":"https://secwatch.observer/filing/0000950170-22-023837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000095017022023837/0000950170-22-023837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000095017022023837/grph-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:49:17.832945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"960d6cf26fe7bd7021eae7c50e7792a65f299f11","claim":"LENZ Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $24.7 million, or $0.45 per basic and diluted share, EPS $0.45 per basic and diluted share.","evidence_excerpt":"Graphite Bio, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017022023837/0000950170-22-023837-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss was $24.7 million, or $0.45 per basic and diluted share"},{"label":"EPS","value":"$0.45 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}